AR047382A1 - Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento - Google Patents

Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento

Info

Publication number
AR047382A1
AR047382A1 ARP050100101A ARP050100101A AR047382A1 AR 047382 A1 AR047382 A1 AR 047382A1 AR P050100101 A ARP050100101 A AR P050100101A AR P050100101 A ARP050100101 A AR P050100101A AR 047382 A1 AR047382 A1 AR 047382A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
halo
secretagogs
useful
Prior art date
Application number
ARP050100101A
Other languages
English (en)
Inventor
Weixu Zhai
Samuel W Gerritz
Charles J Andres
Joseph A Tino
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR047382A1 publication Critical patent/AR047382A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Reivindicacion 1:Un compuesto de acuerdo con la formula (1), caracterizado porque cada R1 en cada caso se selecciona independientemente del grupo que consiste de hidrogeno, alquilo, arilo, hidroxi, oxialquilo, oxiperfluoroalquilo, halo, amino, carboaminoalquilo y carboaminocarboalquilo, en donde cada alquilo, arilo oxialquilo, amino, carboaminoalquilo y carboaminocarboalquilo, pueden sustituirse opcionalmente con uno o más alquilo, arilo, hidroxi, oxialquilo, oxiperfluoroalquilo, halo, amino, carboaminalquilo, aminoarboalquilo o carboaminocarboalquilo; R2 se selecciona del grupo que consiste de H y alquilo; R3 en cada caso se selecciona independientemente del grupo que consiste de hidrogeno, alquilo y halo; R4 se selecciona del grupo que consiste de hidrogeno, alquilo y halo; R4 se selecciona del grupo que consiste de H y alquilo X es (CH2)n; y n es 0 o 1, en donde la formula (1) es inclusive todos los profármacos, ésteres de profármacos, estereoisomeros y sales farmacéuticamente aceptables de la formula (1).
ARP050100101A 2004-01-13 2005-01-12 Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento AR047382A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53612804P 2004-01-13 2004-01-13

Publications (1)

Publication Number Publication Date
AR047382A1 true AR047382A1 (es) 2006-01-18

Family

ID=34806987

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100101A AR047382A1 (es) 2004-01-13 2005-01-12 Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento

Country Status (5)

Country Link
US (1) US7214804B2 (es)
AR (1) AR047382A1 (es)
PE (1) PE20051054A1 (es)
TW (1) TW200530181A (es)
WO (1) WO2005070884A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
DK2425715T3 (da) * 2005-08-31 2014-04-28 Univ Tennessee Res Foundation Behandling af symptomer på nyresygdom med selektive, androgenreceptor modulatorer (SARM)
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
EA019849B1 (ru) * 2006-08-28 2014-06-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Способ лечения, подавления, ингибирования или уменьшения инцидентов симптомов, ассоциированных с почечным заболеванием: гипогонадизма и непроизвольной потери веса
US9371297B2 (en) 2007-02-09 2016-06-21 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
CA2709677C (en) 2007-12-21 2017-03-14 Lin Zhi Selective androgen receptor modulators (sarms) and uses thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
HUE052574T2 (hu) 2012-07-13 2021-05-28 Oncternal Therapeutics Inc Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
MX2021012690A (es) 2019-04-19 2022-01-31 Ligand Pharm Inc Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
US20240166612A1 (en) * 2021-02-18 2024-05-23 X-Biotix Therapeutics, Inc. Arylthioether acetamide and related compounds and their use in treating medical conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US6194578B1 (en) 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues

Also Published As

Publication number Publication date
TW200530181A (en) 2005-09-16
US7214804B2 (en) 2007-05-08
US20050154043A1 (en) 2005-07-14
PE20051054A1 (es) 2005-12-16
WO2005070884A3 (en) 2006-05-26
WO2005070884A2 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
AR047382A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
CR9980A (es) Imidazolinas 4,4,5,5 tetrasustituidas
MX2009010024A (es) Nuevo compuesto de adenina.
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
ECSP045317A (es) Piridinoilpiperidinas como agonistas de 5-ht1f
ES2531324T3 (es) Intermedio para producir un derivado de gamma-aminoácido bicíclico
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
AR039672A1 (es) Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat)
PE20040636A1 (es) Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
TW200745117A (en) Macrocylic inhibitors of hepatitis C virus
UY32606A (es) Sulfonamidas nematocidas
PH12012501030A1 (en) Anti-tumor effect potentiator
ECSP088773A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
TW200612958A (en) Substituted imidazole derivatives
NO20082877L (no) Forloperforbindelse til radioaktiv halogenmerket organisk forbindelse
SV2010003459A (es) Derivados de pirimidina 934
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
AR111272A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con arilo farmacológicamente activos
CR9472A (es) Derivados de aminoacidos
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
NI201100035A (es) Agentes antifúngicos.
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.

Legal Events

Date Code Title Description
FB Suspension of granting procedure